摘要
目的:探讨阿戈美拉汀、盐酸帕罗西汀治疗老年期抑郁症的有效性及对睡眠质量的影响。方法:选取2021年2月-2022年2月于福建省级机关医院睡眠医学中心治疗的老年期抑郁症患者152例作为研究对象,随机数字表法将其分为阿戈美拉汀组76例与帕罗西汀组76例。阿戈美拉汀组采用阿戈美拉汀治疗,帕罗西汀组使用盐酸帕罗西汀治疗,分别对两组抑郁自评量表(SDS)、汉密尔顿抑郁量表(HAMD)、匹兹堡睡眠质量指数(PSQI)、Herth希望量表(Herth hope index,HHI)得分情况进行评估,对比两组炎症因子水平及不良反应、临床疗效。结果:阿戈美拉汀组治疗8周后FGF-22水平及HHI评分高于帕罗西汀组,MPO、TNF-α、IL-1β水平及SDS、HAMD、PSQI评分均低于帕罗西汀组(P<0.05)。阿戈美拉汀组治疗总有效率优于帕罗西汀组(P<0.05)。阿戈美拉汀组不良反应发生率略低于帕罗西汀组,但差异无统计学意义(P>0.05)。结论:阿戈美拉汀治疗可显著改善患者抑郁情绪,有较好的临床效果,能促进患者身体恢复,效果较为理想。
Objective:To explore the effectiveness of Agomelatine and Paroxetine Hydrochloride in the treatment of old-age depression and its influence on sleep quality.Method:A total of 152 old-age depression patients treated in Fujian Provincial Government Hospital Sleep Medicine Center from February 2021 to February 2022 were selected as the study subjects and divided into 76 patients in the Agomelatine group and 76 patients in the Paroxetine group.Agomelatine group was treated with Agomelatine,Paroxetine group was treated with Paroxetine Hydrochloride.The self-rating depression scale (SDS),Hamilton depression scale (HAMD),Pittsburgh sleep quality index (PSQI) and Herth hope index (HHI) scores of two groups were calculated,and the levels of inflammatory indicators,adverse effects and clinical efficacy of two groups were compared.Result:The FGF-22 level and HHI score of Agomelatine group after 8 weeks of treatment were higher than those of Paroxetine group,while the MPO,TNF-α,IL-1β levels,SDS,HAMD,and PSQI scores were lower than those of Paroxetine group (P<0.05).The total effective rate of Agomelatine group was better than that of Paroxetine group (P<0.05).The incidence of adverse reactions in Agomelatine group was slightly lower than that in Paroxetine group,but the difference was not statistically significant (P>0.05).Conclusion:Agomelatine treatment can significantly improve the patients’ depression,has a good clinical effect,promote the physical recovery of patients,the effect is more ideal.
作者
莫夸耀
MO Kuayao(Fujian Provincial Government Hospital,Fuzhou 350003,China)
出处
《中外医学研究》
2022年第32期22-25,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH